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Endoscopic ultrasonography (EUS) technology has undergone a great deal of progress along with 
the color and power Doppler imaging, three-dimensional imaging, electronic scanning, tissue 
harmonic imaging, and elastography, and one of the most important developments is the ability 
to acquire contrast-enhanced images. The blood flow in small vessels and the parenchymal 
microvasculature of the target lesion can be observed non-invasively by contrast-enhanced 
EUS (CE-EUS). Through a hemodynamic analysis, CE-EUS permits the diagnosis of various 
gastrointestinal diseases and differential diagnoses between benign and malignant tumors. 
Recently, mechanical innovations and the development of contrast agents have increased the 
use of CE-EUS in the diagnostic field, as well as for the assessment of the efficacy of therapeutic 
agents. The advances in and the current status of CE-EUS are discussed in this review.
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Introduction
Matsuda and Yabuuchi [1] first introduced the concept of contrast-enhanced abdominal 
ultrasonography (CE-US) in 1986. With the use of an intra-arterial infusion of carbon dioxide as the 
contrast material, CE-US had diagnostic utility because the signal emitted by the CO2 microbubbles 
was detected in real time during fundamental B-mode US. Kato et al. [2] first introduced contrast-
enhanced endoscopic US (CE-EUS) with the use of an intra-arterial CO2 infusion. However, a limitation 
of these methods was that US was only possible during an angiographic examination. In the mid-
1990s, EUS with a color/power Doppler function became possible, and the development of sonicated 
serum albumin, injected into a peripheral vein, enabled enhanced US, acquiring images without 
angiography [3-5]. The development of CO2 microbubbles and the progress of technical innovations, 
such as harmonic imaging, have resulted in improvements in the visualization of target lesions, 
increasing the utility of CE-EUS. Harmonic imaging visualizes microvessels and parenchymal perfusion 
by decreasing artifacts, such as blooming, in US [6].
In general, CE-EUS is categorized into two types: CE-EUS with the Doppler method (CE-EUS-D) 
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and CE-EUS with harmonic imaging (CE-EUS-H). CE-EUS-D helps 
to distinguish between vascular-rich and hypovascular areas of 
a target lesion. CE-EUS-H provides a more detailed vasculature 
image of the target lesion [7]. Due to the differences between the 
two modes, information about the target lesion can be obtained 
and characterized depending on the purpose. Furthermore, the 
contrast-enhanced images acquired with CE-EUS can be subjected 
to quantitative analyses using Inflow Time Mapping (Hitachi Aloka 
Medical, Tokyo, Japan) and time-intensity curve (TIC) patterns to 
objectively characterize the target lesions [7]. Additionally, three-
dimensional (3D) CE-EUS can provide positive information regarding 
the relationship between the target location and the locations of 
adjacent organs and blood vessels via 3D reconstructed images 
[8-10]. Such progress in the development of CE-EUS has enabled 
the characterization of microvascularization, which can be used in 
the differential diagnosis of benign and malignant focal lesions as 
well as to improve the staging guidance for therapeutic procedures. 
In this review, we describe the current status of CE-EUS and the 
direction of future developments.
Contrast Agents
Contrast agents, used in CE-EUS and injected into peripheral veins, 
are an important factor in enhancing ultrasonograms. Contrast 
agents generally consist of gas-filled microbubbles, encapsulated by 
a phospholipid or albumin shell. They are classified into three types 
on the basis of their capability for transpulmonary passage and their 
half-life in the human body [7,11]. Commercially available contrast 
agents are listed in Table 1. The first ultrasound contrast agent (UCA) 
was Levovist (Bergkamen, Germany), consisting of microbubbles of 
air, covered by galactose and palmitic acid [12]. When this agent is 
used, contrast-enhanced harmonic imaging requires high acoustic 
power to oscillate or break the Levovist microbubbles. However, 
the EUS instrument is equipped with only a small transducer, 
and therefore, the transmission signals are too low to oscillate or 
break the Levovist microbubbles. In contrast, second-generation 
contrast agents for US, such as SonoVue (Milan, Italy), Sonazoid 
(Little Chalfont, UK), and Definity (N. Billerica, MA, USA), can be 
oscillated or even broken with a small transducer [12]. Due to the 
limited acoustic power of EUS, second-generation agents are more 
appropriate for EUS [13]. The only third-generation agent currently 
available is Echogen (Washington, DC, USA), which undergoes a 
phase shift from liquid to gas at body temperature [14]. The contrast 
agents that are currently in use are relatively safe, and no severe or 
long-lasting adverse effects have yet been reported in humans [11].
Clinical Applications: Diagnosis
Through a hemodynamic analysis with enhanced images obtained 
using contrast agents, CE-EUS can be used in the differential 
diagnosis of various gastrointestinal diseases. Topics that are being 
researched in conjunction with various diseases are discussed below.
Pancreatic Disease
Because EUS can acquire high-resolution images of the pancreas, 
it is considered a highly sensitive method for evaluating and 
diagnosing pancreatic lesions, when compared with other imaging 
modalities [15,16]. However, EUS has limitations in evaluating 
intratumoral vascular structures or enhancement patterns in the 
characterization of pancreatic lesions because it lacks enhancing 
Table 1. Contrast agents for ultrasonography 
Contrast agents Composition Manufacturer
First generation
    Albunex 5% Sonicated serum 





    Echovist 





    Levovist 
    (SHU 508)
Stabilized, standardized 
microbubbles with 
galactose, 0.1% palmitic 
acid shell
Schering
    Myomap Albumin shell Quadrant 
(Nottingham, UK)
    Qantison Albumin shell Quadrant
    Sonavist Cyanoacrylate shell Schering
Second generation
    Definity/luminity C3F8 with lipid stabilizer 
shell
Bristol-Myers Squibb 
Medical Imaging (N. 
Billerica, MA, USA)
    Sonazoid C4F10 with lipid stabilizer 
shell
GE Healthcare (Little 
Chalfont, UK)
    Imagent-imavist C6F14 with lipid stabilizer 
shell
Alliance (San Diego, 
CA, USA)
    Optison C3F8 with denatured human 
albumin shell
GE Healthcare
    Bisphere/
    cardiosphere
Polylactide-coglycolide 
shell with albumin overcoat
Commercially 
unavailable
    SonoVue SF6 gas with lipid stabilizer 
shell
Bracco (Milan, Italy)





    Echogen Dodecafluoropentane 




Modified from Reddy et al. [11].
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technology. To overcome the limitations of EUS, CE-EUS evaluates 
vascularity using contrast agents to characterize the lesion(s) 
[17-27]. In a meta-analysis, the sensitivity and the specificity of 
differentially diagnosing pancreatic adenocarcinoma using CE-EUS 
were reported to be 94% and 89%, respectively [20]. CE-EUS helps 
in visualizing the microvasculature of a pancreatic lesion to permit 
the characterization of intertumoral structures. This characterization 
can help in the diagnosis of pancreatic ductal adenocarcinoma in 
difficult cases by permitting the observation of hypovascularity, one 
of the signs of ductal adenocarcinoma [6,17] (Fig. 1). In particular, 
the utility of CE-EUS has been reported to include differentiation of 
focal pancreatitis and carcinomas [4,28,29], preoperative localization 
of pancreatic endocrine tumors [30,31], differentiation of mural 
nodules in intraductal papillary mucinous neoplasms, and detection 
of malignant transformations [32,33] (Fig. 2). CE-EUS images 
showed irregular vascularization with only arterial and no venous 
vessels in pancreatic cancer but regular vascularization with the 
detection of venous vessels in focal pancreatitis [4]. This difference 
may be attributed to the relatively high pressure inside a ductal 
adenocarcinoma of the pancreas due to the surrounding fibrous 
tissues. Pancreatic cancer has been shown to be a hypoperfused 
lesion, in comparison with the surrounding normal pancreatic 
parenchyma, but an inflammatory mass has been demonstrated as 
a hyperperfused or isoperfused lesion in CE-EUS [28]. Furthermore, 
various approaches have been proposed for differentiating between 
pancreatic adenocarcinoma and pancreatic disease. Vascularity 
can be analyzed quantitatively by generating TIC while performing 
CE-EUS [7,18,34,35]. Maximum intensity, accumulated intensity 
during observation, intensity reduction rate, and the ratio between 
the uptake by the mass and the uptake by the surrounding 
parenchyma are measured through quantitative analyses, using 
TIC, and are useful in differentiating autoimmune pancreatitis, 
pseudotumors, neuroendocrine tumors, and carcinomas [18,34-36]. 
The maximal intensity and the maximal accumulated intensity (peak 
intensity minus base intensity before contrast injection) of pancreatic 
carcinoma were significantly lower than in autoimmune pancreatitis 
[35]. The echo intensity reduction rate from the peak at 1 minute 
was greatest in pancreatic cancer, followed by mass-forming 
pancreatitis, autoimmune pancreatitis, and neuroendocrine tumor 
[34]. The contrast uptake levels in pancreatic adenocarcinoma and 
chronic pancreatitis were significantly lower than in the surrounding 
tissue. However, the contrast uptake ratio compared with the 
surrounding tissue in a pancreatic ductal adenocarcinoma was 
significantly lower than in chronic pancreatitis [18]. In another study, 
the signal intensity compared with the parenchyma and maximal 
intensity in pancreatic adenocarcinoma was lower than in chronic 
pseudotumoral pancreatitis, while the time to peak was significantly 
greater in pancreatic carcinoma than in pseudotumoral pancreatitis 
[36]. CE-EUS can also be used for T-staging of pancreatobiliary 
carcinomas by observing the invasion at the portal vein more 
accurately than with EUS [37].
While EUS-guided fine-needle aspiration (EUS-FNA) has assumed 
an important role in the pathological diagnosis of pancreatic 
masses, it sometimes fails when used to identify diffusely infiltrating 
pancreatic carcinoma, particularly in patients with chronic 
pancreatitis or a recent episode of acute pancreatitis [38]. In such 
Fig. 1. Typical contrast-enhanced harmonic endoscopic ultrasonography (EUS) image of pancreatic carcinoma.
A. Conventional EUS shows a hypoechoic lesion (arrowheads) with an indistinct margin in the head of the pancreas. B. Contrast-enhanced 
harmonic EUS reveals the lesion as a hypovascular heterogeneous mass with the vessels (arrows) protruding into the cancer.
A B
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cases, CE-EUS can be useful for observing the lesion and finding a 
suitable target lesion for EUS-FNA [25,27,39]. In certain studies, 
CE-EUS has been reported to complement EUS-FNA by assisting in 
the differentiation of a pancreatic adenocarcinoma that had been 
overlooked as a false negative while using EUS-FNA. However, there 
is disagreement as to whether CE-EUS can serve sufficiently as a 
complete replacement for EUS-FNA [17,27]. CE-EUS may serve as 
a complementary tool for EUS-FNA in difficult situations due to an 
intervening vessel or anticoagulation therapy.
Gallbladder
CE-EUS can facilitate the identification of the depth of cancer 
invasion in the diagnosis of gallbladder (GB) cancer. By enhancing 
the first and the third layer of the GB wall, we can improve the 
resolution between the GB wall structure and a cancerous lesion, 
assisting in T-staging by differentiating between T1b and T1a tumors 
with greater accuracy [7,40] (Fig. 3). The depth of tumor infiltration 
was determined according to the TNM classification, as follows: T1, 
hypoechoic tumor invades the first (T1a) or the second layer (T1b); 
and T2, hypoechoic tumor invades the third hyperechoic layer with 
no extension beyond the third layer or into the liver. CE-EUS can 
show a three-layer structure consisting of hyperechoic, hypoechoic, 
and hyperechoic layers from the GB luminal side. The echogenic first 
and third layers are enhanced and the intactness of the three-layer 
structure can be distinguished by CE-EUS. In one study, the accuracy 
of EUS in depicting the depth of tumor invasion was 78.6%, which 
is lower than the 92.9% accuracy of CE-EUS [40]. Furthermore, 
CE-EUS can not only differentiate between infiltrating and exophytic 
GB cancer but also between benign GB diseases, including chronic 
cholecystitis, which exhibit three intact GB layers, and cholesterol 
polyps [3]. Moreover, CE-EUS can facilitate the differentiation of 
GB adenoma and cholesterol polyps according to the homogeneity 
and size of the GB polyps and their enhancement patterns [41] 
(sensitivity, 75%; specificity, 66.6%) (Fig. 4); most adenomas show 
homogeneous enhancement, while the cholesterol polyps show 
heterogeneous enhancement patterns.
Gastrointestinal Tract Disease
Through the enhancement of the third and the fifth layer of the 
esophageal and gastric walls, CE-EUS can assist in the evaluation of 
the depth of invasion of esophageal and gastric adenocarcinoma, 
with greater accuracy (90%) than EUS (76.7%) [42,43]. Furthermore, 
in terms of CE-EUS with TIC, the echo intensity of gastrointestinal 
stromal tumors (GIST) can assist in differentiation because 
Fig. 2. Image of neuroendocrine tumor on contrast-enhanced harmonic endoscopic ultrasonography (EUS).
A. Conventional EUS demonstrates a hypoechoic lesion (arrowheads) with a round shape and a distinct margin in the body of the pancreas. B. 
Contrast-enhanced harmonic EUS shows the lesion as a rather hypervascular heterogeneous mass with a clear margin and vessels protruding 
into the mass (arrows). In the arterial phase, the lesion was enhanced as a hypervascular homogeneous mass; this difference could enable 
the viewer to distinguish a neuroendocrine tumor from a ductal carcinoma in the pancreas.
A B
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Fig. 3. Application of contrast-enhanced harmonic endoscopic ultrasonography (EUS) in the staging of gallbladder cancer.
A. Conventional EUS shows a solid lesion (arrowheads) in the gallbladder. The depth of gallbladder wall invasion is not clearly seen. B. The 
first and third layer of the gallbladder were enhanced by contrast-enhanced harmonic EUS, and the depth of invasion can be identified more 
clearly. Because the first layer (arrowhead) appears to be broken without the discontinuity of the third layer (arrow), the stage was diagnosed 
as T2, which was pathologically confirmed after surgery.
A B
Fig. 4. Enhancement patterns of contrast-enhanced endoscopic ultrasonography (EUS) of gallbladder adenoma and cholesterol polyp.
A. Gallbladder adenoma shows a lobulated contour and a homogeneous enhancement after the injection of the contrast agent. B. 
Cholesterol polyp shows a rather heterogeneous enhancement due to lipid-laden macrophages and the presence of few microvessels with a 
heterogeneous distribution.
A B
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54]. CE-EUS with microspheres monitors the altered pancreatic 
perfusion of an ablated pancreatic lesion, allowing the detection of 
the vascularity at the necrosis site, which can be useful in follow-up 
with a post-ablation treatment [55].
Tumor blood flow is generally associated with metastatic 
potential and poor prognosis [11]. The quantity of vascular signals, 
measured with CE-US, has been reported to be useful in the early 
assessment and monitoring of the efficacy of antiangiogenic agents 
for pancreatic ductal carcinoma before morphological changes 
occur [56]. The quantity of vascular signals detected from pancreatic 
ductal carcinoma by CE-US correlated with tumor characteristics and 
vascular endothelial growth factor (VEGF) expression [57]. The rate 
of hepatic metastasis and the VEGF expression were significantly 
higher in patients with high vascular signals than in those with 
almost no vascular signal. Furthermore, CE-US may be a feasible 
technology for molecular imaging of the expression of VEGF receptor 
type 2 (VEGFR2) [58]. After UCAs conjugated with an anti-VEGFR2 
monoclonal antibody or an isotype control antibody were randomly 
injected into breast cancer cells implanted in athymic nude mice, the 
sonograms were analyzed by calculating the intensity amplitudes, 
and the tumor samples were harvested for the analysis of VEGFR2 
expression. The mean intensity amplitude caused by a backscatter 
of the retained VEGFR2-targeted UCA was significantly higher than 
that of the control UCA. This study showed that targeted CE-US may 
enable in vivo molecular imaging of VEGFR2 expression in the tumor 
vascular endothelium and may be used for non-invasive longitudinal 
evaluation of tumor angiogenesis in preclinical studies. It is expected 
that CE-EUS will be used to assess the efficacy of antitumoral 
agents in pancreatic cancer because of the feasibility of these new 
technologies using CE-US. 
One study reported the usefulness of CE-EUS in predicting the 
efficacy of chemotherapy in patients with inoperable pancreatic 
cancer prior to the actual chemotherapy [58]. Using images from the 
early image phase (10-40 seconds after injection of the contrast 
materials), researchers considered the vessel sign to be positive 
when large (diameter, ≥1 mm), irregular subepithelial intratumoral 
vessels flowing from the periphery to the center of the tumor were 
detected by CE-EUS. Patients with a positive vessel sign showed 
significantly longer overall survival and progression-free survival 
than patients with a negative vessel sign.
Discussion
Through technical innovations in EUS and the development of 
contrast agents, the use of CE-EUS has been expanded to many 
diseases. The various applications of CE-EUS include differentiating 
benign from malignant lesions of the pancreas, GB, LNs, and other 
their values are higher than those of other benign tumors [44]. 
Additionally, with the use of CE-EUS, irregular vessels that enter from 
the periphery to the center of the GIST can be visualized for high-
grade GISTs; thus, CE-EUS can be used to evaluate the malignant 
potential of GIST [45].
Lymph Nodes
CE-EUS plays an important role in the detection of lymph node 
(LN) metastasis. Although EUS-FNA is useful in the pathological 
confirmation of LN status, CE-EUS can be useful in cases of 
mediastinal and abdominal LNs that do not approach the aspiration 
yield [46,47]. CE-EUS can detect a filling defect, which is a typical 
sign of malignant lymphadenopathy, with a sensitivity of 100% 
and a specificity of 84% [46]. Furthermore, CE-EUS can be used 
to clearly observe the microvasculature of intra-abdominal lesions 
of undetermined origins, which can facilitate the differentiation 
of malignant from benign lesions, because of the homogeneous 
enhancement of benign lesions [48]. As such, it is expected that 
CE-EUS with respect to the LN status can be used for the N-staging 
of digestive tract tumors.
Other Diseases
Various clinical applications of vessel visualization by CE-EUS 
are being implemented. Color Doppler EUS and CE-EUS can 
be combined to evaluate the morphological and hemodynamic 
characteristics of visceral vascular diseases, which can be useful for 
the diagnosis of splanchnic artery disease [49]. It can also be used 
to determine the appropriate treatment of isolated mesenteric artery 
dissection [49]. In this report, it was suggested that the intimal 
flap and blood flow within the true lumen in patients with celiac 
artery dissection be evaluated with CE-EUS; further, it was reported 
that this information is useful in deciding the medical treatment 
or surgery. Enhanced vessels and the third echogenic layer of the 
esophageal wall can be visualized to detect perforating veins and 
periesophageal varices [50]. Cholecystoduodenal fistulas have also 
been detected by means of an enhancement of the gastrointestinal 
tract using CE-EUS [51].
Clinical Applications: Treatment Monitoring
Although no direct therapeutic procedure can be performed with it, 
CE-EUS serves as a monitoring tool for a range of disease entities. 
Many studies are being conducted to expand the role of CE-EUS in 
the evaluation of the effects of treatments of such diseases. One 
of the greatest strengths of CE-EUS, the visualization of vessel 
function, makes this possible. For the treatment of focal pancreatic 
lesions, EUS-guided pancreatic tissue ablation has been used [52-
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gastrointestinal lesions, as well as assessing the depth of invasion of 
esophageal, gastric, and GB cancers for tumor staging. Additionally, 
CE-EUS can indicate tumor neovascularization using contrast agents. 
CE-EUS imaging is useful in assessing and monitoring the efficacy of 
antiangiogenic agents, and allows molecular imaging by quantifying 
tumor perfusion.
CE-EUS is significantly more sensitive and accurate than 
conventional EUS in detecting the relatively hypovascular ductal 
adenocarcinomas of the pancreas due to its enhancement ability 
[4,5,25,28]. CE-EUS imaging improves the depiction of pancreatic 
tumors, enabling the detection of small lesions that may be 
uncertain in conventional EUS because of biliary stents or chronic 
pancreatitis [25]. In terms of the efficacy of CE-EUS and conventional 
EUS in preoperative T-staging of pancreatobiliary tumors, CE-EUS is 
more accurate than conventional EUS (rate of misdiagnosis: CE-EUS 
vs. EUS=7.6% vs. 23%) [37]. 
Additionally, the efficacy of CE-EUS in the differential diagnosis of 
small pancreatic tumors was superior to that of contrast-enhanced 
multidetector-row CT (MDCT) in two comparative studies [5,27]. 
Although CE-EUS and MDCT did not differ significantly in diagnostic 
ability with respect to all pancreatic masses, CE-EUS exhibited the 
highest sensitivity in differentiating between pancreatic ductal 
carcinoma and other tumors in pancreatic masses <2 cm in diameter 
(CE-EUS, 83%; EUS, 11%; MDCT, 50%) [5]. 
Occasionally, CE-EUS can differentiate small pancreatic carcinomas 
that cannot be detected by other imaging modalities [15,27]. In 
one study, seven ductal carcinomas and two neuroendocrine tumors 
showed hypoenhancement and hyperenhancement, respectively, 
on CH-EUS in 12 neoplasms that were not detected by MDCT [27]. 
CE-EUS may be a promising method to detect and characterize small 
pancreatic tumors that cannot be identified by other imaging tools 
[59]. Enhancement patterns demonstrated by CE-EUS during the 
subsequent vascular phase (e.g., arterial and venous phases) can be 
similar to MDCT [60].
An advantage of CE-EUS is its ability to assess the contrast 
enhancement patterns in real time with a substantially higher 
temporal resolution than other imaging modalities without the 
need to predefine scan time points or perform bolus tracking [60]. 
Furthermore, repeated administration of contrast agents during 
CE-EUS is possible due to the excellent patient tolerance of such 
agents.
However, although CE-EUS further improved the efficacy of 
EUS in terms of the characterization of target lesions by allowing 
visualization of microvessels and parenchymal perfusion, the analysis 
of the enhanced images is subjective and operator-dependent. 
To overcome these limitations, Inflow Time Mapping has been 
proposed as a new tool for an objective quantitative evaluation [7]. 
Three-dimensional CE-EUS may also be useful in reducing operator-
dependence because the enhanced images are obtained by the free-
hand movement of the endoscope during CE-EUS [8,9]. However, 
the clinical applications of these new techniques are at present 
restricted to case reports and a few studies; further large-scale 
studies are needed.
In conclusion, conceptual innovations and continuous technical 
developments have enabled CE-EUS to be used as a supplementary 
or additive tool with other cross-sectional and dynamic imaging 
modalities like computed tomography and magnetic resonance 
imaging.
ORCID: Sung Ill Jang: http://orcid.org/0000-0003-4937-6167; Dong Ki Lee: 
http://orcid.org/0000-0002-0048-9112
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
References
 1. Matsuda Y, Yabuuchi I. Hepatic tumors: US contrast enhancement 
with CO2 microbubbles. Radiology 1986;161:701-705.
 2. Kato T, Tsukamoto Y, Naitoh Y, Hirooka Y, Furukawa T, Hayakawa T. 
Ultrasonographic and endoscopic ultrasonographic angiography in 
pancreatic mass lesions. Acta Radiol 1995;36:381-387.
 3. Hirooka Y, Naitoh Y, Goto H, Ito A, Taki T, Hayakawa T. Usefulness of 
contrast-enhanced endoscopic ultrasonography with intravenous 
injection of sonicated serum albumin. Gastrointest Endosc 
1997;46:166-169. 
 4. Hocke M, Schulze E, Gottschalk P, Topalidis T, Dietrich CF. Contrast-
enhanced endoscopic ultrasound in discrimination between focal 
pancreatitis and pancreatic cancer. World J Gastroenterol 2006;12: 
246-250. 
 5. Sakamoto H, Kitano M, Suetomi Y, Maekawa K, Takeyama Y, Kudo 
M. Utility of contrast-enhanced endoscopic ultrasonography for 
diagnosis of small pancreatic carcinomas. Ultrasound Med Biol 
2008;34:525-532.
 6. Kitano M, Sakamoto H, Matsui U, Ito Y, Maekawa K, von Schrenck 
T, et al. A novel perfusion imaging technique of the pancreas: 
contrast-enhanced harmonic EUS (with video). Gastrointest Endosc 
2008;67:141-150.
 7. Hirooka Y, Itoh A, Kawashima H, Ohno E, Itoh Y, Nakamura Y, et 
al. Contrast-enhanced endoscopic ultrasonography in digestive 
diseases. J Gastroenterol 2012;47:1063-1072.
 8. Saftoiu A, Gheonea DI. Tridimensional (3D) endoscopic ultrasound: 
a pictorial review. J Gastrointestin Liver Dis 2009;18:501-505.
 9. Hocke M, Dietrich CF. New technology: combined use of 3D 
contrast enhanced endoscopic ultrasound techniques. Ultraschall 
Med 2011;32:317-318.
Sung Ill Jang, et al.
168  Ultrasonography 33(3), July 2014 e-ultrasonography.org
10. Hocke M, Ignee A, Dietrich CF. Three-dimensional contrast-
enhanced endoscopic ultrasound for the diagnosis of autoimmune 
pancreatitis. Endoscopy 2011;43 Suppl 2 UCTN:E381-E382. 
11. Reddy NK, Ioncica AM, Saftoiu A, Vilmann P, Bhutani MS. Contrast-
enhanced endoscopic ultrasonography. World J Gastroenterol 
2011;17:42-48. 
12. Kitano M, Sakamoto H, Kudo M. Contrast-enhanced endoscopic 
ultrasound. Dig Endosc 2014;26 Suppl 1:79-85. 
13. Romagnuolo J, Hoffman B, Vela S, Hawes R, Vignesh S. Accuracy 
of contrast-enhanced harmonic EUS with a second-generation 
perflutren lipid microsphere contrast agent (with video). 
Gastrointest Endosc 2011;73:52-63.
14. Maresca G, Summaria V, Colagrande C, Manfredi R, Calliada F. New 
prospects for ultrasound contrast agents. Eur J Radiol 1998;27 
Suppl 2:S171-S178.
15. Kitano M, Kudo M, Sakamoto H, Komaki T. Endoscopic ultrasono-
graphy and contrast-enhanced endoscopic ultrasonography. 
Pancreatology 2011;11 Suppl 2:28-33.
16. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, 
Imperiale TF, et al. Comparison of endoscopic ultrasonography and 
multidetector computed tomography for detecting and staging 
pancreatic cancer. Ann Intern Med 2004;141:753-763.
17. Napoleon B, Alvarez-Sanchez MV, Gincoul R, Pujol B, Lefort 
C, Lepilliez V, et al. Contrast-enhanced harmonic endoscopic 
ultrasound in solid lesions of the pancreas: results of a pilot study. 
Endoscopy 2010;42:564-570.
18. Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O. 
Quantitative contrast-enhanced harmonic endoscopic ultrasono-
graphy for the discrimination of solid pancreatic masses. Ultraschall 
Med 2010;31:571-576.
19. Kitano M, Sakamoto H, Komaki T, Kudo M. New techniques and 
future perspective of EUS for the differential diagnosis of pancreatic 
malignancies: contrast harmonic imaging. Dig Endosc 2011;23 
Suppl 1:46-50. 
20. Gong TT, Hu DM, Zhu Q. Contrast-enhanced EUS for differential 
diagnosis of pancreatic mass lesions: a meta-analysis. Gastrointest 
Endosc 2012;76:301-309.
21. Xu C, Li Z, Wallace M. Contrast-enhanced harmonic endoscopic 
ultrasonography in pancreatic diseases. Diagn Ther Endosc 
2012;2012:786239.
22. De Angelis C, Brizzi RF, Pellicano R. Endoscopic ultrasonography for 
pancreatic cancer: current and future perspectives. J Gastrointest 
Oncol 2013;4:220-230.
23. Lee TY, Cheon YK, Shim CS. Clinical role of contrast-enhanced 
harmonic endoscopic ultrasound in differentiating solid lesions 
of the pancreas: a single-center experience in Korea. Gut Liver 
2013;7:599-604.
24. Park JS, Kim HK, Bang BW, Kim SG, Jeong S, Lee DH. Effectiveness 
of contrast-enhanced harmonic endoscopic ultrasound for the 
evaluation of solid pancreatic masses. World J Gastroenterol 
2014;20:518-524.
25. Fusaroli P, Spada A, Mancino MG, Caletti G. Contrast harmonic 
echo-endoscopic ultrasound improves accuracy in diagnosis of solid 
pancreatic masses. Clin Gastroenterol Hepatol 2010;8:629-634.
26. Hirooka Y, Goto H, Ito A, Hayakawa S, Watanabe Y, Ishiguro Y, et 
al. Contrast-enhanced endoscopic ultrasonography in pancreatic 
diseases: a preliminary study. Am J Gastroenterol 1998;93:632-
635. 
27. Kitano M, Kudo M, Yamao K, Takagi T, Sakamoto H, Komaki T, et al. 
Characterization of small solid tumors in the pancreas: the value 
of contrast-enhanced harmonic endoscopic ultrasonography. Am J 
Gastroenterol 2012;107:303-310.
28. Becker D, Strobel D, Bernatik T, Hahn EG. Echo-enhanced color- 
and power-Doppler EUS for the discrimination between focal 
pancreatitis and pancreatic carcinoma. Gastrointest Endosc 
2001;53:784-789.
29. Hocke M, Ignee A, Dietrich CF. Advanced endosonographic 
diagnostic tools for discrimination of focal chronic pancreatitis 
and pancreatic carcinoma: elastography, contrast enhanced 
high mechanical index (CEHMI) and low mechanical index 
(CELMI) endosonography in direct comparison. Z Gastroenterol 
2012;50:199-203.
30. Ishikawa T, Itoh A, Kawashima H, Ohno E, Matsubara H, Itoh Y, et 
al. Usefulness of EUS combined with contrast-enhancement in the 
differential diagnosis of malignant versus benign and preoperative 
localization of pancreatic endocrine tumors. Gastrointest Endosc 
2010;71:951-959.
31. Kasono K, Hyodo T, Suminaga Y, Sugiura Y, Namai K, Ikoma A, et 
al. Contrast-enhanced endoscopic ultrasonography improves the 
preoperative localization of insulinomas. Endocr J 2002;49:517-
522. 
32. Yamashita Y, Ueda K, Itonaga M, Yoshida T, Maeda H, Maekita T, 
et al. Usefulness of contrast-enhanced endoscopic sonography 
for discriminating mural nodules from mucous clots in intraductal 
papillary mucinous neoplasms: a single-center prospective study. J 
Ultrasound Med 2013;32:61-68.
33. Ohno E, Itoh A, Kawashima H, Ishikawa T, Matsubara H, Itoh Y, 
et al. Malignant transformation of branch duct-type intraductal 
papillary mucinous neoplasms of the pancreas based on contrast-
enhanced endoscopic ultrasonography morphological changes: 
focus on malignant transformation of intraductal papillary 
mucinous neoplasm itself. Pancreas 2012;41:855-862. 
34. Matsubara H, Itoh A, Kawashima H, Kasugai T, Ohno E, Ishikawa 
T, et al. Dynamic quantitative evaluation of contrast-enhanced 
endoscopic ultrasonography in the diagnosis of pancreatic diseases. 
Pancreas 2011;40:1073-1079.
35. Imazu H, Kanazawa K, Mori N, Ikeda K, Kakutani H, Sumiyama K, 
et al. Novel quantitative perfusion analysis with contrast-enhanced 
Contrast-enhanced endoscopic ultrasonography
e-ultrasonography.org Ultrasonography 33(3), July 2014 169
harmonic EUS for differentiation of autoimmune pancreatitis from 
pancreatic carcinoma. Scand J Gastroenterol 2012;47:853-860. 
36. Gheonea DI, Streba CT, Ciurea T, Saftoiu A. Quantitative low 
mechanical index contrast-enhanced endoscopic ultrasound for the 
differential diagnosis of chronic pseudotumoral pancreatitis and 
pancreatic cancer. BMC Gastroenterol 2013;13:2. 
37. Imazu H, Uchiyama Y, Matsunaga K, Ikeda K, Kakutani H, Sasaki 
Y, et al. Contrast-enhanced harmonic EUS with novel ultrasono-
graphic contrast (Sonazoid) in the preoperative T-staging for 
pancreaticobiliary malignancies. Scand J Gastroenterol 2010;45: 
732-738.
38. Bhutani MS, Gress FG, Giovannini M, Erickson RA, Catalano MF, 
Chak A, et al. The No Endosonographic Detection of Tumor (NEST) 
Study: a case series of pancreatic cancers missed on endoscopic 
ultrasonography. Endoscopy 2004;36:385-389.
39. Ueda K, Yamashita Y, Itonaga M. Real-time contrast-enhanced 
endoscopic ultrasonography-guided fine-needle aspiration (with 
video). Dig Endosc 2013;25:631.
40. Hirooka Y, Naitoh Y, Goto H, Ito A, Hayakawa S, Watanabe Y, et 
al. Contrast-enhanced endoscopic ultrasonography in gallbladder 
diseases. Gastrointest Endosc 1998;48:406-410. 
41. Park CH, Chung MJ, Oh TG, Park JY, Bang S, Park SW, et al. 
Differential diagnosis between gallbladder adenomas and 
cholesterol polyps on contrast-enhanced harmonic endoscopic 
ultrasonography. Surg Endosc 2013;27:1414-1421.
42. Nomura N, Goto H, Niwa Y, Arisawa T, Hirooka Y, Hayakawa T. 
Usefulness of contrast-enhanced EUS in the diagnosis of upper GI 
tract diseases. Gastrointest Endosc 1999;50:555-560.
43. Zheng Z, Yu Y, Lu M, Sun W, Wang F, Li P, et al. Double contrast-
enhanced ultrasonography for the preoperative evaluation of 
gastric cancer: a comparison to endoscopic ultrasonography with 
respect to histopathology. Am J Surg 2011;202:605-611.
44. Kannengiesser K, Mahlke R, Petersen F, Peters A, Ross M, Kucharzik 
T, et al. Contrast-enhanced harmonic endoscopic ultrasound is able 
to discriminate benign submucosal lesions from gastrointestinal 
stromal tumors. Scand J Gastroenterol 2012;47:1515-1520.
45. Sakamoto H, Kitano M, Matsui S, Kamata K, Komaki T, Imai H, et al. 
Estimation of malignant potential of GI stromal tumors by contrast-
enhanced harmonic EUS (with videos). Gastrointest Endosc 
2011;73:227-237. 
46. Kanamori A, Hirooka Y, Itoh A, Hashimoto S, Kawashima H, 
Hara K, et al. Usefulness of contrast-enhanced endoscopic 
ultrasonography in the differentiation between malignant and 
benign lymphadenopathy. Am J Gastroenterol 2006;101:45-51.
47. Hocke M, Menges M, Topalidis T, Dietrich CF, Stallmach A. Contrast-
enhanced endoscopic ultrasound in discrimination between benign 
and malignant mediastinal and abdominal lymph nodes. J Cancer 
Res Clin Oncol 2008;134:473-480.
48. Xia Y, Kitano M, Kudo M, Imai H, Kamata K, Sakamoto H, et al. 
Characterization of intra-abdominal lesions of undetermined origin 
by contrast-enhanced harmonic EUS (with videos). Gastrointest 
Endosc 2010;72:637-642. 
49. Paik WH, Choi JH, Seo DW, Cho YP, Park DH, Lee SS, et al. Clinical 
usefulness with the combination of color Doppler and contrast-
enhanced harmonic EUS for the assessment of visceral vascular 
diseases. J Clin Gastroenterol 2013 [Epub]. http://dx.doi.org/10.1097/
MCG.0000000000000032. 
50. Ernst H, Nusko G, Hahn EG, Heyder N. Color Doppler endosono-
graphy of esophageal varices: signal enhancement after intravenous 
injection of the ultrasound contrast agent Levovist. Endoscopy 
1997;29:S42-S43. 
51. Velosa M, Lopes S, Castro R, Macedo G. Cholecystoduodenal 
fistula diagnosed with contrast-enhanced endoscopic ultrasound. 
Endoscopy 2013;45 Suppl 2 UCTN:E18-E19. 
52. Chang KJ. EUS-guided fine needle injection (FNI) and anti-tumor 
therapy. Endoscopy 2006;38 Suppl 1:S88-S93. 
53. Verna EC, Dhar V. Endoscopic ultrasound-guided fine needle 
injection for cancer therapy: the evolving role of therapeutic 
endoscopic ultrasound. Therap Adv Gastroenterol 2008;1:103-109. 
54. Jurgensen C, Schuppan D, Neser F, Ernstberger J, Junghans 
U, Stolzel U. EUS-guided alcohol ablation of an insulinoma. 
Gastrointest Endosc 2006;63:1059-1062.
55. Giday SA, Magno P, Gabrielson KL, Buscaglia JM, Canto MI, Ko 
CW, et al. The utility of contrast-enhanced endoscopic ultrasound 
in monitoring ethanol-induced pancreatic tissue ablation: a pilot 
study in a porcine model. Endoscopy 2007;39:525-529.
56. Ohshima T, Yamaguchi T, Ishihara T, Yoshikawa M, Kobayashi 
A, Sakaue N, et al. Evaluation of blood flow in pancreatic 
ductal carcinoma using contrast-enhanced, wide-band Doppler 
ultrasonography: correlation with tumor characteristics and vascular 
endothelial growth factor. Pancreas 2004;28:335-343.
57. Lyshchik A, Fleischer AC, Huamani J, Hallahan DE, Brissova M, 
Gore JC. Molecular imaging of vascular endothelial growth factor 
receptor 2 expression using targeted contrast-enhanced high-
frequency ultrasonography. J Ultrasound Med 2007;26:1575-1586.
58. Yamashita Y, Ueda K, Itonaga M, Yoshida T, Maeda H, Maekita T, 
et al. Tumor vessel depiction with contrast-enhanced endoscopic 
ultrasonography predicts efficacy of chemotherapy in pancreatic 
cancer. Pancreas 2013;42:990-995.
59. Kitano M, Sakamoto H, Kudo M. Endoscopic ultrasound: contrast 
enhancement. Gastrointest Endosc Clin N Am 2012;22:349-358. 
60. Giovannini M. Contrast-enhanced endoscopic ultrasound 
and elastosonoendoscopy. Best Pract Res Clin Gastroenterol 
2009;23:767-779.
